| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding | |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | Entrez:930 MIM:107265 HGNC:HGNC:1633 Ensembl:ENSG00000177455 AllianceGenome:HGNC:1633 | |
| Description | CD19 molecule | |||||
| Gene symbol | MS4A1 | Synonyms | B1, Bp35, CD20, CVID5, FMC7, LEU-16, S7 | Type of gene | protein-coding | |
| Chromosome | 11 | Map location | 11q12.2 | dbXrefs | Entrez:931 MIM:112210 HGNC:HGNC:7315 Ensembl:ENSG00000156738 AllianceGenome:HGNC:7315 | |
| Description | membrane spanning 4-domains A1 | |||||
| GTO ID | GTC3907 |
| Trial ID | NCT06464185 |
| Disease | B-Cell Non-Hodgkin's Lymphoma |
| Altered gene | CD3|CD19|CD20 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CAR-T cells |
| Co-treatment | Obinutuzumab|Glofitamab |
| Phase | Phase1|Phase2 |
| Recruitment status | Recruiting |
| Title | A Prospective Clinical Study of CD3-CD20 Bisspecific Antibody Based Therapy Combined With CD19-CAR T Cells in the Treatment of Relapsed Refractory B-cell Non-Hodgkin Lymphoma |
| Year | 2024 |
| Country | China |
| Company sponsor | Institute of Hematology & Blood Diseases Hospital, China |
| Other ID(s) | IIT2024021 |
| Cohort 1 | |||||||||||
|
|||||||||||